Stockscreener 앱 받기
13.84
2.88%
-0.41
전일 마감가:
$14.25
열려 있는:
$14.03
하루 거래량:
155.42K
Relative Volume:
0.53
시가총액:
$401.62M
수익:
$66.59M
순이익/손실:
$-104.93M
주가수익비율:
-2.796
EPS:
-4.95
순현금흐름:
$-96.48M
1주 성능:
+6.71%
1개월 성능:
+7.20%
6개월 성능:
+101.75%
1년 성능:
+136.18%
1일 변동 폭
$13.82
$14.38
1주일 범위
$13.18
$15.55
52주 변동 폭
$4.09
$17.15
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
명칭
Enanta Pharmaceuticals Inc
전화
617 607 0800
주소
4 KINGSBURY AVENUE, WATERTOWN, MA
Compare ENTA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
13.84 | 413.51M | 66.59M | -104.93M | -96.48M | -4.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-14 | 개시 | JP Morgan | Overweight |
| 2025-10-01 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-07-28 | 재개 | H.C. Wainwright | Buy |
| 2023-08-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-08-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-12-09 | 개시 | H.C. Wainwright | Buy |
| 2022-07-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-06-01 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-09-09 | 개시 | SVB Leerink | Mkt Perform |
| 2021-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-11-24 | 개시 | Evercore ISI | Underperform |
| 2020-08-28 | 재개 | ROTH Capital | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-07-27 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-05-24 | 개시 | Wolfe Research | Outperform |
| 2019-04-23 | 업그레이드 | Berenberg | Hold → Buy |
| 2018-12-13 | 개시 | Berenberg | Hold |
| 2018-06-06 | 개시 | ROTH Capital | Buy |
| 2018-02-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-07-11 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | Barclays | Underweight |
| 2015-10-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2015-10-23 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
모두보기
Enanta Pharmaceuticals Inc 주식(ENTA)의 최신 뉴스
What Makes Enanta Pharmaceuticals (ENTA) a New Buy Stock - Yahoo Finance
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Equities Analysts Issue Forecasts for ENTA Q2 Earnings - MarketBeat
Analysts Are Updating Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Estimates After Its First-Quarter Results - simplywall.st
The Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) First-Quarter Results Are Out And Analysts Have Published New Forecasts - 富途牛牛
Enanta (ENTA) Announces $150 Million Mixed Securities Shelf Registration - GuruFocus
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for - PharmiWeb.com
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting - BioSpace
Enanta Pharma (ENTA): Analyst Reiterates Buy Rating with $20 PT - GuruFocus
HC Wainwright Reaffirms "Buy" Rating for Enanta Pharmaceuticals (NASDAQ:ENTA) - MarketBeat
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025 - BioSpace
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 202 - PharmiWeb.com
Enanta Pharmaceuticals (ENTA) Reports Strong Q1 Revenue and Fina - GuruFocus
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Enanta Pharmaceuticals (NASDAQ:ENTA) Posts Earnings Results, Beats Estimates By $0.12 EPS - MarketBeat
Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot - KVUE
Enanta Pharmaceuticals: Overview of Fiscal First Quarter Earnings - Bitget
Enanta Pharma Earnings Review: Q1 Summary - Benzinga
The Technical Signals Behind (ENTA) That Institutions Follow - Stock Traders Daily
Earnings Preview For Enanta Pharma - Benzinga
Enanta Pharmaceuticals (ENTA) Projected to Post Quarterly Earnings on Monday - MarketBeat
Rate Hike: Does Enanta Pharmaceuticals Inc have consistent dividend growthPortfolio Performance Report & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Insider Sell: What are Asset Entities Incs technical support levelsMarket Trend Report & High Accuracy Trade Alerts - baoquankhu1.vn
Precision Trading with Enanta Pharmaceuticals Inc. (ENTA) Risk Zones - Stock Traders Daily
Enanta (NASDAQ: ENTA) seeks 1.6M-share boost to 2019 equity plan - Stock Titan
CEO Moves: Why is Enanta Pharmaceuticals Inc stock going up2025 Market WrapUp & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Sentiment Review: What are Enanta Pharmaceuticals Inc.’s technical support levelsDividend Hike & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Guidance Update: Why is SWKH stock going downSwing Trade & Verified Short-Term Plans - baoquankhu1.vn
Enanta Pharmaceuticals to Present at the Wells Fargo Securities 2013 Healthcare Conference - AOL.com
Why Enanta Pharmaceuticals Inc. stock appeals to analystsJobs Report & Free Long-Term Investment Growth Plans - bollywoodhelpline.com
Technical Reactions to ENTA Trends in Macro Strategies - Stock Traders Daily
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
JPM26: Enanta outlines strategy to lead in RSV therapeutics - Yahoo Finance
Chipmakers Recap: Is Enanta Pharmaceuticals Inc stock affected by interest rate hikesPortfolio Update Report & Free Technical Pattern Based Buy Signals - Bộ Nội Vụ
Income Plays: What makes Enanta Pharmaceuticals Inc. stock attractive to growth fundsJuly 2025 Market Mood & Growth Focused Entry Point Reports - Bộ Nội Vụ
Downgrade Watch: Why is Enanta Pharmaceuticals Inc stock going upJuly 2025 Summary & Trade Opportunity Analysis - baoquankhu1.vn
Is Enanta Pharmaceuticals Inc. stock trading at a premium valuationJuly 2025 Trade Ideas & Reliable Trade Execution Plans - ulpravda.ru
Will Enanta Pharmaceuticals Inc. stock gain from strong economyAnalyst Downgrade & Safe Swing Trade Setups - Улправда
Enanta Pharmaceuticals, Inc.Common Stock (NQ: ENTA - FinancialContent
What makes Enanta Pharmaceuticals Inc. stock attractive to growth fundsTrade Execution Strategies & Our Experts Decode Market Noise for You - bollywoodhelpline.com
Enanta advances RSV and immunology pipeline with key milestones ahead By Investing.com - Investing.com Nigeria
Enanta Pharmaceuticals (NASDAQ:ENTA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Enanta Pharma (ENTA) Receives Buy Rating, Price Target Maintained | ENTA Stock News - GuruFocus
Baird reiterates Outperform rating on Enanta Pharmaceuticals stock By Investing.com - Investing.com Canada
Will Enanta Pharmaceuticals Inc. stock benefit from automationQuarterly Portfolio Summary & Daily Oversold Bounce Ideas - Улправда
Is Enanta Pharmaceuticals Inc. stock a safe haven assetWeekly Trend Report & Weekly Stock Breakout Alerts - ulpravda.ru
What valuation multiples suggest for Enanta Pharmaceuticals Inc. stock2025 Breakouts & Breakdowns & Fast Moving Market Watchlists - Улправда
Is Enanta Pharmaceuticals Inc. stock a bargain at current levelsJuly 2025 Rallies & Risk Controlled Daily Plans - Улправда
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook - PharmiWeb.com
Enanta advances RSV and immunology pipeline with key milestones ahead - Investing.com
Trading the Move, Not the Narrative: (ENTA) Edition - Stock Traders Daily
Enanta Pharmaceuticals Inc (ENTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.19%
자본화:
|
볼륨(24시간):